Monday, October 19, 2020 7:06:05 AM
https://www.google.com/amp/s/www.usnews.com/news/health-news/articles/2020-10-16/who-addresses-gileads-pushback-on-remdesivir-trial%3fcontext=amp
AND they have access to UNblinded HGEN - Lenzilumab-Yescarta data - Cytokine storm In CAR-T is Cytokine storm in COVID- O’Day can treat two storms with one deal.
https://clinicaltrials.gov/ct2/show/NCT04314843?term=Lenzilumab&draw=2&rank=2
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM